Crackdown On Substandard Ayurvedic Medicines

THIRUVANANTHAPURAM: Various batches of ayurvedic medicines of Rajasthan Herbal International Pvt Ltd have been found to be of substandard quality during quality tests conducted at the drug testing laboratories of the State Drugs Controller’s Department. Following this, the Ayurvedic Drugs Control Department banned the distribution and sale of these medicines.

 

Traders and hospitals holding stock of drugs should return the same to the distributor and inform the District Ayurvedic Drugs Inspectors concerned, the officials said. Name and batch number of medicines are: Pain Niwaran Churna (PNF21057), Dr Relaxi Capsule (DRG21019), Pain Niwaran Churna (PNK21089), Mood on Forever (MCE21003), Dr Relaxi Capsule (DRK21030), Dr Relaxi Oil (DOD21004), Dama Buti Churna (DBH21017), Asthalex Capsule (ALK21004).

Related Posts

Low Bone Density in Nearly 7 in 10 Patients Pointing to High Risk of Osteoporosis

Releasing One- Year DEXA analysis, Aakash Healthcare red flags stressing Early Detection and Timely Intervention.  New Delhi: On the occasion of World Osteoporosis Day, Aakash Healthcare has released an analysis…

Hat Trick of PhDs in Health: Three Cheers for the Rare Researcher

The Prodigy got appointed Pro- VC of a Health Science University when He was just 33 Three Years ago. Nagpur/ Wardha: Three PhDs in health!!! Such rare accomplishment is the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Low Bone Density in Nearly 7 in 10 Patients Pointing to High Risk of Osteoporosis

Low Bone Density in Nearly 7 in 10 Patients Pointing to High Risk of Osteoporosis

Hat Trick of PhDs in Health: Three Cheers for the Rare Researcher

Hat Trick of PhDs in Health: Three Cheers for the Rare Researcher

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27